mp3 dönüştür

We are experts in myeloma…
it’s all we do

 

Our singular focus on myeloma ensures that we bring unparalleled expertise and dedication to everything we do

 

From actionable insights to strategic engagement with leading KOLs and community clinicians, our full suite of  services empowers you to lead in the myeloma market

Everything you need to navigate the myeloma market

Insights

MYInsights provides real-time insights to data being presented at conferences or from the latest publications. Gain an understanding of how the experts view the data.

Data Compass conference reports. Collecting insights at medical conferences shouldn’t be hard. MYELOMA360 makes it easy!

Engagements

MYBoard is a new format for Advisory Boards.

In place of single company events, MYBoard is an independent full day advisory board fully managed by MYELOMA360, with four 2-hour time slots for multiple companies, allowing for a focused, efficient, dedicated session to generate insights around your strategic objectives.

Strategy & Consulting

We are a team of seasoned biopharmaceutical specialists dedicated to helping companies strategize and plan their marketing, clinical development and medical affairs activities.

Our expertise is focused in myeloma across the full development lifecycle, allowing us to provide tailored solutions to drive your company’s success.

Everything you need to navigate the myeloma market

Latest insights

Myeloma News

EU panel backs approval of under-the-skin Sarclisa for myeloma

A European Medicines Agency (EMA) panel has recommended approval of a subcutaneous (under-the-skin) version of Sarclisa (isatuximab), an approved myeloma treatment sold by Sanofi. The recommendation, from the EMA’s Committee for Medicinal Products for Human Use...

Management of hematological toxicities after BCMA-directed CAR-T cell therapy

Source: Myeloma : nature.com subject feeds Post Content Read More

Revised criteria for light chain MGUS enhance diagnostic accuracy and risk stratification

Source: Myeloma : nature.com subject feeds Post Content Read More

Merck acquisition brings Terns CML treatment into pipeline

Merck is set to acquire Terns Pharmaceuticals in a $6.7 billion deal aimed at expanding its oncology pipeline, including an experimental treatment for chronic myeloid leukemia (CML). The acquisition will give Merck access to Terns’ lead candidate, TERN-701, an oral...
Latest Data

Latest Publications

Risk factors for infections in patients with multiple myeloma: a systematic review and meta-analysis

Front Oncol. 2026 Mar 12;16:1726340. doi: 10.3389/fonc.2026.1726340. eCollection 2026. ABSTRACT...

Non-ICANS Neurologic Toxicity after BCMA CAR T: A systematic review and meta-analysis of 4630 multiple myeloma patients

Blood Adv. 2026 Mar 26:bloodadvances.2026019617. doi: 10.1182/bloodadvances.2026019617. Online...

Systematic literature review of secondary primary malignancies related to a CAR-T treatment in patients with multiple myeloma, lymphoma or leukemia

Cancer Treat Res Commun. 2026 Feb 28;47:101161. doi: 10.1016/j.ctarc.2026.101161. Online ahead of...

Assessment tools for peripheral neuropathy in multiple myeloma

Korean J Intern Med. 2026 Mar;41(2):230-241. doi: 10.3904/kjim.2025.281. Epub 2026 Mar 1. ABSTRACT...

Early intervention for high-risk smoldering multiple myeloma (SMM)

Cochrane Database Syst Rev. 2026 Mar 18;3:CD015494. doi: 10.1002/14651858.CD015494.pub2. ABSTRACT...

Email

info@myeloma360.com

bahisliongalabet1xbet